CPC A61L 27/362 (2013.01) [A61L 27/3604 (2013.01); A61L 27/3687 (2013.01); A61L 27/3691 (2013.01)] | 22 Claims |
1. A non-wild type, biologically engineered swine for producing live cells and tissue that vascularize after xenotransplantation,
wherein said swine has a biologically engineered genome such that it does not express one or more extracellular surface glycan epitopes,
wherein said swine is free of at least the following zoonotic pathogens:
(i) Ascaris species, cryptosporidium species, Echinococcus, Strongyloids sterocolis, and Toxoplasma gondii in fecal matter;
(ii) Leptospira species, Mycoplasma hyopneumoniae, porcine reproductive and respiratory syndrome virus (PRRSV), pseudorabies, transmissible gastroenteritis virus (TGE)/Porcine Respiratory Coronavirus, and Toxoplasma Gondii as determined by antibody titers;
(iii) Porcine Influenza;
(iv) the following bacterial pathogens as determined by bacterial culture: Bordetella bronchisceptica, Coagulase-positive staphylococci, Coagulase-negative staphylococci, Livestock-associated methicillin resistant Staphylococcus aureus (LA MRSA), Microphyton and Trichophyton spp.;
(v) Porcine cytomegalovirus; and
(vi) Brucella suis;
wherein said swine has been maintained according to a bioburden-reducing procedure in an isolated closed herd,
wherein all other animals in the isolated closed herd have been confirmed to be free of said zoonotic pathogens, and
wherein the swine was isolated from contact with any non-human animals and animal housing facilities outside of the isolated closed herd.
|